IBT reduced its operating loss as R&D costs fell after completing its Phase III study. The FDA granted Breakthrough Therapy Designation to IBP-9414, accelerating its path to market. Cash reserves are sufficient for planned activities into mid-2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.